Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-1726 in Participants With Obesity
NCT06252220Phase 1Recruiting
- Sponsor
- NeuroBo Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Nov 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DA-1726 in obesity (3 arms), sponsored by NeuroBo Pharmaceuticals. Primary endpoint: Treatment-related adverse events at 24 weeks. Started Mar 2024; status: recruiting.
02
Drugs
DA-1726
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06252220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06252220.